Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI

BACKGROUND: Patients who undergo percutaneous coronary intervention (PCI) are at increased risk for recurrent cardiovascular events despite aggressive medical therapy. METHODS AND RESULTS: This post hoc analysis focused on the subset of patients with prior PCI enrolled in REDUCE-IT (Reduction of Car...

Full description

Bibliographic Details
Main Authors: Ballantyne, C.M (Author), Bhatt, D.L (Author), Brinton, E.A (Author), Budoff, M.J (Author), Doyle, R.T., Jr (Author), Gibson, C.M (Author), Giugliano, R.P (Author), Granowitz, C. (Author), Jacobson, T.A (Author), Jiao, L. (Author), Juliano, R.A (Author), Ketchum, S.B (Author), Miller, M. (Author), Peterson, B.E (Author), Pinto, D. (Author), Steg, P.G (Author), Tardif, J.-C (Author), Verma, S. (Author)
Format: Article
Language:English
Published: American Heart Association Inc. 2022
Subjects:
eicosapentaenoic acid
icosapent ethyl
prevention
revascularization
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items